Emergency-use authorization granted for AI-based COVID management

The FDA has cleared an AI startup based in Israel to market its predictive-analytics product to ICUs during the present pandemic.

Clew Medical announced the emergency-use authorization June 16, saying its ICU-specific platform can identify patients at heightened risk of developing life-threatening COVID complications such as respiratory failure and hemodynamic instability.

The company says it trained its AI models on nearly 100,000 ICU patients.

The software, called ClewICU, works as a web application and is intended for use in tele-ICU settings as well as local ICUs.

The idea is to give COVID care teams advance warning on patients at greatest risk of serious symptoms, the company adds, which can increase time available for intervening early, planning ahead and allocating resources enterprise- or community-wide.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.